Leap Therapeutics (NASDAQ:LPTX – Get Free Report) and Dyne Therapeutics (NASDAQ:DYN – Get Free Report) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, institutional ownership, analyst recommendations, risk, valuation and profitability.
Insider & Institutional Ownership
30.5% of Leap Therapeutics shares are owned by institutional investors. Comparatively, 96.7% of Dyne Therapeutics shares are owned by institutional investors. 11.3% of Leap Therapeutics shares are owned by insiders. Comparatively, 20.8% of Dyne Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Analyst Ratings
This is a summary of recent ratings and recommmendations for Leap Therapeutics and Dyne Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Leap Therapeutics | 0 | 0 | 4 | 0 | 3.00 |
| Dyne Therapeutics | 0 | 0 | 7 | 1 | 3.13 |
Valuation and Earnings
This table compares Leap Therapeutics and Dyne Therapeutics’ gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Leap Therapeutics | $1.50 million | 54.44 | -$81.41 million | ($5.08) | -0.63 |
| Dyne Therapeutics | N/A | N/A | -$235.94 million | ($3.97) | -6.57 |
Leap Therapeutics has higher revenue and earnings than Dyne Therapeutics. Dyne Therapeutics is trading at a lower price-to-earnings ratio than Leap Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Leap Therapeutics and Dyne Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Leap Therapeutics | N/A | -133.17% | -90.90% |
| Dyne Therapeutics | N/A | -171.52% | -124.20% |
Risk & Volatility
Leap Therapeutics has a beta of 0.54, meaning that its stock price is 46% less volatile than the S&P 500. Comparatively, Dyne Therapeutics has a beta of 1, meaning that its stock price has a similar volatility profile to the S&P 500.
Summary
Dyne Therapeutics beats Leap Therapeutics on 7 of the 13 factors compared between the two stocks.
About Leap Therapeutics
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.
About Dyne Therapeutics
Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
Receive News & Ratings for Leap Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leap Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
